RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.
Combining bulk and single-cell RNA-sequencing data to develop an NK cell-related prognostic signature for hepatocellular carcinoma based on an integrated machine learning framework.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
本研究构建了基于 NK 细胞相关基因的基因特征,为 HCC 患者的预后与免疫治疗反应评估提供了新平台。
分子靶向治疗和免疫疗法显著延长了肝细胞癌(HCC)患者的生存期,但多药耐药和高度分子异质性仍限制临床获益进一步提高。肿瘤浸润自然杀伤(NK)细胞功能障碍与 HCC 进展及患者生存获益密切相关。因此,本研究建立 NK 细胞相关预后特征,用于预测 HCC 患者预后和免疫治疗应答。
从 GSE162616 数据集的单细胞 RNA-seq 数据中筛选 NK 细胞标志物。研究开发了包含 77 种算法的集成机器学习框架,并在 TCGA-LIHC、GSE14520、GSE76427 和 ICGC-LIRI-JP 数据集中建立基因特征模型。另使用 GSE91061 和 PRJEB23709 数据集外部验证其预测免疫检查点抑制剂(ICI)应答的效能。
结合 LASSO 和 CoxBoost 算法建立了 11 基因特征模型,其一致性指数在 77 种算法中最高,并据此将患者分为高风险和低风险组。该预后特征模型对总生存率具有良好预测性能,预测准确度中至高,并且在 TCGA、GEO 和 ICGC 队列中均是 HCC 预后的独立危险因素。与高风险组相比,低风险患者具有更高的 IPS-PD1 阻断剂评分、IPS-CTLA4 阻断剂评分及常见免疫检查点表达,同时 TIDE 评分较低,提示低风险患者更可能从 ICI 治疗中获益。此外,真实世界队列 PRJEB23709 也显示低风险组免疫治疗应答更好。
本研究基于 NK 细胞相关基因开发了基因特征模型,为 HCC 患者预后和免疫治疗应答评估提供了新平台。
The application of molecular targeting therapy and immunotherapy has notably prolonged the survival of patients with hepatocellular carcinoma (HCC). However, multidrug resistance and high molecular heterogeneity of HCC still prevent the further improvement of clinical benefits. Dysfunction of tumor-infiltrating natural killer (NK) cells was strongly related to HCC progression and survival benefits of HCC patients. Hence, an NK cell-related prognostic signature was built up to predict HCC patients' prognosis and immunotherapeutic response.
NK cell markers were selected from scRNA-Seq data obtained from GSE162616 data set. A consensus machine learning framework including a total of 77 algorithms was developed to establish the gene signature in TCGA-LIHC data set, GSE14520 data set, GSE76427 data set and ICGC-LIRI-JP data set. Moreover, the predictive efficacy on ICI response was externally validated by GSE91061 data set and PRJEB23709 data set.
With the highest C-index among 77 algorithms, a 11-gene signature was established by the combination of LASSO and CoxBoost algorithm, which classified patients into high- and low-risk group. The prognostic signature displayed a good predictive performance for overall survival rate, moderate to high predictive accuracy and was an independent risk factor for HCC patients' prognosis in TCGA, GEO and ICGC cohorts. Compared with high-risk group, low-risk patients showed higher IPS-PD1 blocker, IPS-CTLA4 blocker, common immune checkpoints expression but lower TIDE score, which indicated low-risk patients might be prone to benefiting from ICI treatment. Moreover, a real-world cohort, PRJEB23709, also revealed better immunotherapeutic response in low-risk group.
Overall, the present study developed a gene signature based on NK cell-related genes, which offered a novel platform for prognosis and immunotherapeutic response evaluation of HCC patients.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。